Imagine a specialized protein from rattlesnake venom that acts like a key, fitting perfectly into receptors on lung cancer cells to shut them down. Instead of harsh chemicals that attack the whole body, this treatment targets the cancer cells specifically to trigger their self-destruction. It is delivered through a simple pump at home, making it much easier for patients than staying in a hospital.
Late-stage non-small cell lung cancer (NSCLC) has very low survival rates and current treatments like chemotherapy cause severe side effects. There is a critical need for effective, low-toxicity treatments that can be administered outside of a hospital setting.
A naturally derived receptor binding protein (CB-24) and a scalable production pipeline including a 100-snake breeding colony and GMP manufacturing protocols.
If you are a drug developer dealing with the low survival rates of late-stage NSCLC — this project developed CB-24, a receptor binding protein that induces cell death in lung carcinoma cells. It offers a safer alternative to chemotherapy with minimal side effects.
If you are a home-care provider dealing with the burden of hospital-based cancer infusions — this project developed a user-friendly at-home monotherapy using infusion pumps. This allows stage 3 and 4 patients to receive treatment in their own environment.
If you are a manufacturer dealing with the need for high-purity natural toxins — this project developed a breeding colony of 100 South American rattlesnakes to secure raw material. This ensures a stable supply chain for clinical-grade drug production.
Based on available project data, the specific price per dose or treatment cost is not disclosed; however, the project received an EU contribution of EUR 2,499,999 for development.
The company has doubled its snake colony to 100 animals to support Phase II trials and early commercialization. They have also partnered with Immunoclin Ltd to establish GMP manufacturing processes.
Based on available project data, specific patent numbers are not listed, but the project is focused on securing regulatory approvals from the EMA and FDA to market the drug.
The project aims to complete a Phase Ic clinical trial involving 24 patients within a 24-month window to advance toward regulatory approval.
The drug is administered intravenously as a monotherapy using user-friendly infusion pumps at home.
The project is led by a single SME, Celtic Biotech Ltd, indicating a highly centralized control of the technology. While the consortium is small (1 partner), they have successfully outsourced critical manufacturing to a specialized UK firm, Immunoclin Ltd, to implement GMP systems and seek MHRA permits.
Contact Celtic Biotech Ltd in Ireland regarding CB-24 clinical trial partnerships.
Contact us to explore licensing opportunities for this natural oncology therapeutic.
